Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Summit Able To Promote Apex Plus For LASIK At Ophthalmology Conference

This article was originally published in The Gray Sheet

Executive Summary

Summit Technology's receipt on Oct. 21 of FDA approval for its Apex Plus excimer laser for use in laser-assisted in-situ keratomileusis (LASIK) could help the firm increase its market share by 30%, the firm says. Analysts estimate the firm's stake at 20%.

You may also be interested in...

Visx' Star S2 Excimer Laser Approvable For LASIK With Conditions - Panel

A July 22 recommendation that Visx' Star S2 excimer laser be approved for in situ keratomileusis (LASIK) procedures was precipitated by a consensus desire on the part of FDA's Ophthalmic Devices Panel to disseminate study data through product labeling.

Warning Letter Roundup & Recap – 26 January 2021

No device-related warning letters were released by the US FDA the week of 26 January.

EU Crunch Time For Two Drugs That Lost Their Fast-Track Status

Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts